£515.00

The 2023-2028 Outlook for Neuroendocrine Tumor Treatments in India

Subjects

Price data checked 6 days ago

View at Amazon

We'll watch every seller, every day. One email when your price arrives.

It has never been this cheap. We have no record of a lower price.

£515 today · cheaper than every other day in the last 3 months

NEW HERE?

Amazon shows you one price. We show you all of them.

Tosheroon watches Amazon prices so you don't have to. Every product on Amazon has a price history — we make it visible. Set the price you'd actually pay, and we'll email you the second it gets there. No app, no account, one email.

WHAT'S ON THIS PAGE

↓ Price chart
when this has been cheap or pricey

↓ Forecast
where the price is heading next

↓ Statistics
all-time high & low, recent range

↑ Price alert
name your number, we'll email you

Price History & Forecast

Grey patches = out of stock. Cheaper = lower on the chart. Hover for exact prices.

Last 85 days · 85 data points (no recent data)

Historical

Generating forecast…

Price Distribution

Price distribution over 85 days • 1 price levels

Days at Price

Price Analysis

Most common price: £515 (85 days, 100.0%)

Price range: £515 - £515

Price levels: 1 different prices over 85 days

Description

This study covers the latent demand outlook for neuroendocrine tumor treatments across the states, union territories, and cities of India. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across over 4,900 cities in India. For each city in question, the percent share the city is of its state or union territory and of India as a whole is reported. These comparative benchmarks allow the reader to quickly gauge a city vis-à-vis others. This statistical approach can prove very useful to distribution and/or sales force strategies. Using econometric models which project fundamental economic dynamics within each state, union territory, and city, latent demand estimates are created for neuroendocrine tumor treatments. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved. In this report we define the sales of neuroendocrine tumor treatments as including all commonly understood products and/or services falling within this broad category, irrespective of product packaging, formulation, size, or form. Companies participating in this industry include Advanced Accelerator Applications, Amgen, AVEO Oncology, Boehringer Ingelheim International, Bristol-Myers Squibb, Dauntless Pharmaceuticals, Eli Lilly, Exelixis, F. Hoffmann-La Roche, Hutchison MediPharma, Ipsen Pharma, Novartis, Pfizer, Progenics Pharmaceuticals, Sanofi, Tarveda Therapeutics, and Teva Pharmaceuticals Industries. In addition to the sources indicated, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars are averages for the year in question. Future exchange rates are assumed to be constant in the future at the current level (the average of the year of this publication's release in 2022).

Product Specifications

Format: paperback
ASIN: B0BGKL9HLW
Category: Books > Subjects
Domain: Amazon UK
Release Date: 14 September 2022
Listed Since: 28 September 2022

The 2023-2028 Outlook for Neuroendocrine Tumor Treatments in India

It has never been this cheap. We have no record of a lower price.

Price History & Forecast

Price Distribution

Price Analysis

Description

Product Specifications

Similar Products You Might Like

The 2023-2028 Outlook for Neuroendocrine Tumor Treatments in the United States

The 2023-2028 Outlook for Neuroendocrine Tumor Treatments in China

The 2025-2030 World Outlook for Neuroendocrine Tumor Treatments

The 2023-2028 Outlook for Neuroendocrine Tumor Treatments for US Zip Codes

Neuroendocrine Tumors: Surgical Evaluation and Management

Neuroendocrine Tumours: Diagnosis and Management

Neuroendocrine Neoplasia Management: New Approaches for Diagnosis and Treatment

Neuroendocrine Tumors (Current Clinical Oncology)

The Spectrum of Neuroendocrine Neoplasia: A Practical Approach to Diagnosis, Classification and Therapy

The 2023-2028 Outlook for Non-Hodgkin Lymphoma Chemotherapy Therapeutics in India

The 2023-2028 Outlook for Non-Hodgkin Lymphoma Chemotherapy Therapeutics in the United States

The 2023-2028 Outlook for Non-Small Cell Lung Cancer Therapeutics in India

The 2023-2028 Outlook for Non-Small Cell Lung Cancer Therapeutics in the United States

The 2023-2028 Outlook for Brain Tumor Diagnosis and Treatments in India

The 2023-2028 Outlook for Head and Neck Oncology Nutrition in China

The 2016-2021 Outlook for Non-Small Cell Lung Cancer Therapeutics in the United States

The 2023-2028 Outlook for Non-Hodgkin Lymphoma Treatments in the United States

The 2023-2028 Outlook for Non-Small Cell Lung Cancers in India

The 2023 Report on Head and Neck Cancer Diagnostics: World Market Segmentation by City

The 2023-2028 World Outlook for Enteral Nutrition

The 2023-2028 Outlook for Healthcare Nutrition in the United States

The 2023-2028 Outlook for Natural Killer Cell Therapeutics in India

Neuronal and Glioneuronal Tumors of the Central Nervous System (Neurology - Laboratory and Clinical Research Developments)

The 2023-2028 Outlook for Non-Small Cell Lung Cancers in the United States